82 related articles for article (PubMed ID: 25115278)
1. Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.
Hahne JC; Kurz A; Meyer SR; Dietl J; Engel JB; Honig A
Arch Gynecol Obstet; 2015 Jan; 291(1):131-41. PubMed ID: 25115278
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.
Hahne JC; Schmidt H; Meyer SR; Engel JB; Dietl J; Honig A
J Cancer Res Clin Oncol; 2013 Jun; 139(6):905-14. PubMed ID: 23440492
[TBL] [Abstract][Full Text] [Related]
3. PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer.
Honig A; Hahne JC; Meyer S; Kranke P; Häusler S; Diessner J; Dietl J; Engel JB
Anticancer Res; 2012 May; 32(5):2035-41. PubMed ID: 22593485
[TBL] [Abstract][Full Text] [Related]
4. Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition.
Engel JB; Schönhals T; Weidler C; Häusler S; Krockenberger M; Rieger L; Dietl J; Wischhusen J; Honig A
Oncol Rep; 2009 Aug; 22(2):361-7. PubMed ID: 19578778
[TBL] [Abstract][Full Text] [Related]
5. Immune escape of AKT overexpressing ovarian cancer cells.
Hahne JC; Meyer SR; Gambaryan S; Walter U; Dietl J; Engel JB; Honig A
Int J Oncol; 2013 May; 42(5):1630-5. PubMed ID: 23467686
[TBL] [Abstract][Full Text] [Related]
6. Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells.
Engel JB; Hahne JC; Häusler SF; Meyer S; Segerer SE; Diessner J; Dietl J; Honig A
Anticancer Res; 2012 May; 32(5):2063-8. PubMed ID: 22593489
[TBL] [Abstract][Full Text] [Related]
7. Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.
Locatelli SL; Careddu G; Stirparo GG; Castagna L; Santoro A; Carlo-Stella C
Sci Rep; 2016 Oct; 6():35745. PubMed ID: 27767172
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB
Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944
[TBL] [Abstract][Full Text] [Related]
10. Asiatic acid exerts anticancer potential in human ovarian cancer cells via suppression of PI3K/Akt/mTOR signalling.
Ren L; Cao QX; Zhai FR; Yang SQ; Zhang HX
Pharm Biol; 2016 Nov; 54(11):2377-2382. PubMed ID: 26984021
[TBL] [Abstract][Full Text] [Related]
11. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
12. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
14. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
15. The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.
Hernlund E; Olofsson MH; Fayad W; Fryknäs M; Lesiak-Mieczkowska K; Zhang X; Brnjic S; Schmidt V; D'Arcy P; Sjöblom T; De Milito A; Larsson R; Linder S
Eur J Cancer; 2012 Feb; 48(3):396-406. PubMed ID: 22154651
[TBL] [Abstract][Full Text] [Related]
16. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
17. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
19. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Asselin E; Mills GB; Tsang BK
Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
